Commodore Capital LP: COGENT BIOSCIENCES INC (COGT): Quarterly 13F Position History
As of Q1 2026, Commodore Capital LP reported 2,888,007 shares of COGENT BIOSCIENCES INC (COGT), worth $111.2M and representing 6.4% of its 13F equity book. Quarter-over-quarter share count change: + 691,162 (+31.5%) . The position first appeared in Q4 2020 and has been disclosed across 22 13F-HR filings in Pactolio's tracked window.
- 2,888,007Shares Held (Latest Filing)
- $111.2MReported Market Value (Latest Filing)
- 6.4%Portfolio Weight (% of 13F Equity Book)
- +691,162Quarter-over-Quarter Share Change
- +$33.1MQuarter-over-Quarter Value Change
- 9,738,000Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 22 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 2,888,007 | +691,162 | +31.5% | $111.2M | 6.4% | $38.5 |
| Q4 2025 | 2,196,845 | 5,053,155 | -69.7% | $78.0M | 5.2% | $35.5 |
| Q3 2025 | 7,250,000 | +4,938,836 | +213.7% | $104.1M | 5.1% | $14.4 |
| Q2 2025 | 2,311,164 | 6,581,652 | -74.0% | $16.6M | 1.2% | $7.2 |
| Q1 2025 | 8,892,816 | +2,011,187 | +29.2% | $53.3M | 3.9% | $6.0 |
| Q4 2024 | 6,881,629 | 658,301 | -8.7% | $53.7M | 3.9% | $7.8 |
| Q3 2024 | 7,539,930 | 2,198,070 | -22.6% | $81.4M | 5.1% | $10.8 |
| Q2 2024 | 9,738,000 | +3,313,000 | +51.6% | $82.1M | 5.6% | $8.4 |
| Q1 2024 | 6,425,000 | +858,974 | +15.4% | $43.2M | 2.9% | $6.7 |
| Q4 2023 | 5,566,026 | 0 | — | $32.7M | 2.8% | $5.9 |
| Q3 2023 | 5,566,026 | 0 | — | $54.3M | 6.3% | $9.8 |
| Q2 2023 | 5,566,026 | +793,605 | +16.6% | $65.9M | 7.4% | $11.8 |
| Q1 2023 | 4,772,421 | +452,481 | +10.5% | $51.5M | 7.8% | $10.8 |
| Q4 2022 | 4,319,940 | 0 | — | $49.9M | 7.5% | $11.6 |
| Q3 2022 | 4,319,940 | 624,768 | -12.6% | $64.5M | 10.4% | $14.9 |
| Q2 2022 | 4,944,708 | +1,443,940 | +41.2% | $44.6M | 9.4% | $9.0 |
| Q1 2022 | 3,500,768 | +1,219,453 | +53.5% | $26.2M | 5.9% | $7.5 |
| Q4 2021 | 2,281,315 | +368,804 | +19.3% | $19.6M | 4.5% | $8.6 |
| Q3 2021 | 1,912,511 | +544,929 | +39.8% | $16.1M | 4.2% | $8.4 |
| Q2 2021 | 1,367,582 | +98,387 | +7.8% | $11.1M | 3.8% | $8.1 |
| Q1 2021 | 1,269,195 | +509,170 | +67.0% | $11.1M | 4.4% | $8.8 |
| Q4 2020 | 760,025 | — | — | $8.5M | 4.6% | $11.2 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Commodore Capital LP first disclose a COGT position in 13F-HR filings?
Commodore Capital LP first reported COGENT BIOSCIENCES INC (COGT) on its 13F-HR filing for the period ending 2020-12-31 (Q4 2020). The position has appeared on 22 reported quarters within Pactolio's tracked window.
What was Commodore Capital LP's most recent quarter-over-quarter share-count change in COGT?
Between Q4 2025 and Q1 2026, Commodore Capital LP added 691,162 shares of COGT (+31.5%), bringing the total reported position to 2,888,007 shares at a market value of $111.2M.
Does the implied price-per-share represent Commodore Capital LP's cost basis in COGT?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.